| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-12-09 | Bayer Healthcare (Germany) Drugs for Neglected Diseases initiative (DNDi) | emodepside | river blindness or onchocerciasis | collaboration |
Parasitic diseases | Collaboration agreement |
| 2014-12-09 | Pall Corporation (USA - NY) | resignation |
Technology - Services | Resignation | ||
| 2014-12-08 | Pfizer (USA - NY) | nomination | Rare diseases | Nomination | ||
| 2014-12-04 | GE Healthcare (USA - WI) Broad Institute of MIT and Harvard (USA - MA) | CRISPR-Cas9 gene engineering system | licensing |
Technology - Services | Licensing agreement | |
| 2014-12-04 | Sigma-Aldrich (USA - MO) Broad Institute of MIT and Harvard (USA - MA) | CRISPR/Cas technology | licensing |
Technology - Services | Licensing agreement | |
| 2014-12-04 | CTI BioPharma - previously known as Cell Therapeutics (USA - WA) - Teva Pharmaceutical Industries (Israel) | Trisenox® (arsenic trioxide) | acute promyelocytic leukemia | milestone |
Cancer - Oncology | Milestone |
| 2014-12-04 | Qiagen (The Netherlands) altona Diagnostics (Germany) | RealStar® Ebolavirus RT-PCR Kit 1.0 | Ebola fever | distribution |
Infectious diseases - Diagnostic | Distribution agreement |
| 2014-12-03 | Myriad Genetics (USA - UT) | Tumor BRACAnalysis CDx laboratory | BRCA cancers, ovarian cancer | opening of a new laboratory |
Cancer - Oncology - Diagnostic | Opening of new premises |
| 2014-12-03 | Paratek Pharmaceuticals (USA - MA) | chief financial officer | nomination | Infectious diseases | Nomination | |
| 2014-12-03 | Santen Pharmaceutical (Japan) | general manager | nomination | Ophtalmological diseases | Nomination | |
| 2014-12-03 | Alize Pharma (France) New Paradigm Therapeutics (USA - NC) | peptides derived from IGFBP-2 (Insulin-like Growth Factor Binding Protein-2) | bone loss | licensing |
Bone diseases | Licensing agreement |
| 2014-12-03 | Virbac (France) Nexvet (UK) | NV-01 | pain associated with osteoarthritis in dogs | collaboration distribution |
Veterinary medicine | Collaboration agreement |
| 2014-12-02 | Bioversys (Switzerland) Enamine (Ukraine ) | screening services, HTS and ADME profiling services | Infectious diseases | R&D agreement | ||
| 2014-12-02 | Tesaro (USA - MA) AnaptysBio (USA - CA) | bispecific antibody candidate designed to target two undisclosed immune checkpoints | development - licensing | Cancer - Oncology | Licensing agreement | |
| 2014-12-02 | Integragen (France) Inserm Transfert (France) Paris Descartes University (France) | two hepatocellular carcinoma (HCC) molecular signatures | hepatocellular carcinoma | licensing |
Cancer - Oncology | Licensing agreement |
| 2014-12-02 | NeuroVive Pharmaceutical (Sweden) Skåne University Hospital (Sweden) | CicloMulsion® | prevention of acute kidney injury in patients undergoing heart surgery | clinical researcb |
Cardiovascular diseases - Kidney diseases - Renal diseases | Clinical research agreement |
| 2014-12-02 | Dimension Therapeutics (USA - MA) | chief medical officer, vice president | nomination | Rare diseases - Genetic diseases | Nomination | |
| 2014-12-01 | Abbvie (USA - IL) the Medicines Patent Pool (Switzerland) | lopinavir, ritonavir | AIDS | licensing |
Infectious diseases | Licensing agreement |
| 2014-12-01 | Philips (The Netherlands) The Netherlands Cancer Institute (The Netherlands) | collaboration |
Cancer - Oncology | Collaboration agreement | ||
| 2014-12-01 | Gilead Sciences (USA - CA) Mylan (USA - PA) | tenofovir alafenamide | HIV-1 infection | licensing |
Infectious diseases | Licensing agreement |
